Pharmabiz
 

Starr Health picks Sarvotham Remedies as global marketing associate for 'Herbal First'

Y V Phani Raj, HyderabadFriday, July 9, 2004, 08:00 Hrs  [IST]

The Secunderabad-based Sarvotham Remedies has entered into a marketing agreement with the US-based Starr HealthCare Enterprises, as part of which Sarvotham will act as a global marketing associate to promote and sell 'Herbal First' range of products manufactured by Starr Health. Sarvotham will start marketing seven nutraceutical products in India, VV Rao, CEO of Sarvotham, said. Dr Ramesh Ramayya, director of Starr, informed that the seven products that would be marketed in India include 'Prostate First' which relieves symptoms of enlarged prostrate and Prostatitis and also helps in preventing and controlling Prostate Cancer. Another product, 'OvaFirst', controls ovarian diseases and 'Ova Replace First' is for natural management of menopausal syndrome. Others include Vitamen First -to prevent and control stress and strain, Vitawomen First- to prevent stress and strain in women, D'Toxy First- helps cardiovascular system and protects the liver during Hepatitis in addition to preventing and delaying the onset of Cataract, Joints First- provides nutritional support to all the joints of the body besides helping in rebuilding the cartilages and enhancing the mobility of the joints. The products, which have been formally launched in Andhra Pradesh on July 4, are likely to be launched in Karnataka during September, 2004. Later, it will hit Tamil Nadu and Kerala markets by December, this year. The partners are expecting a sales turnover of about Rs 10 crore by the end next financial year. Starr has developed nearly 100 products so far and is keenly looking at exporting its products to various countries. The company is planning to introduce products for anti-ageing, diabetic support, cardiovascular support, a range of sports nutrition products and medicated oils, aromatherapy and organic range of products, Dr Ramesh added. The products will be marketed initially through ethical promotion and later OTC route can be opted, Rao added.

 
[Close]